What is the Origin of GHS Peptide Administration?

The term is derived from the discovery of ghrelin, the natural ligand for the Growth Hormone Secretagogue Receptor (GHSR), and the subsequent development of synthetic molecules that mimic its action. GHS peptides, such as Sermorelin or Ipamorelin, are a class of compounds that have been developed since the late 20th century to modulate the somatotropic axis.

What is the Mechanism of GHS Peptide Administration?

The mechanism of action involves the GHS peptide binding to the GHSR, primarily located on somatotroph cells in the anterior pituitary gland, which triggers a pulsatile release of GH into the bloodstream. Unlike exogenous GH injection, GHS administration maintains the physiological pulsatility of GH release and works through the body's natural feedback loops, thereby promoting a more controlled and sustained elevation of downstream anabolic factors like IGF-1. This action supports muscle maintenance, lipolysis, and bone remodeling.

GHS Peptide Administration ∞ Area

GHS Peptide Administration

Meaning

GHS Peptide Administration refers to the clinical delivery of Growth Hormone Secretagogue (GHS) peptides, which are synthetic or bio-engineered compounds that stimulate the body’s own pituitary gland to release endogenous growth hormone (GH). This therapeutic strategy is utilized to safely and physiologically elevate circulating GH and Insulin-like Growth Factor 1 (IGF-1) levels, particularly in the context of age-related somatopause. The goal is to improve body composition, support tissue repair, and enhance metabolic function.